Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:PGHL

PROCTER & GAMBLE HEALTH L

Healthcare › Pharmaceuticals & Biotechnology·NIFTY MICROCAP 250NIFTY SMALLCAP 500NIFTY TOTAL MARKET
₹5,405.00
at close · 28 Oct 2026
▼ 185.00 (-3.31%)

Latest filings

Next results: Mon, 2 Nov · Financial Results
  1. Compliance certificate for Q2 FY27 demat details filed · Compliance
  2. Board meeting on Nov 2 to consider Q2 and H1 FY26 results · Results
  3. Trading window closure ahead of Q2 results · Compliance
All filings ↓
Ask Nexa about PROCTER & GAMBLE HEALTH L

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Sells vitamins, minerals and supplements in India under brands like Neurobion (B-vitamin / nerve care), Evion (Vitamin E / muscle health), Livogen (iron), and Polybion, distributed mainly through pharmacies and increasingly through e-pharmacy platforms. The portfolio is concentrated in nerve care, muscle health and iron deficiency, with recent launches in gummy and cream formats such as Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. Distribution runs on a super-distributor go-to-market model that has expanded Neurobion's pharmacy reach by 1.4x in five years, adding roughly 100,000 new stores. Exports contributed ₹50 crore (+12% YoY) with the Sri Lanka business growing 30%+. The business is asset-light (capex 1.1% of revenue), with materials being the largest cost at 21.8% of revenue, followed by employee costs at 15.8% and other operating expenses at 25.8%, and it generated operating cash flow of ₹338 crore in FY26.

Operating scale
5-year sales CAGR
7%FY21 to FY26
5-year PAT CAGR
13%FY21 to FY26
Pharmacy reach expansion
1.4x in 5 years (~100,000 new stores)5 years to FY25
Exports
₹50 crore (+12% YoY)FY25
Sri Lanka business growth
30%+FY25
Indian VMS category growth
9% CAGRindustry
Who pays it
Indian retail consumers, primarily through pharmacies and e-pharmacy platforms
Biggest cost
Materials (raw materials and packaging) at 21.8% of revenue
Kind of business
Brand-led, asset-light vitamins and supplements company with high margins and low capital intensity
Where it sits
Market leader in Vitamin E with Evion; record unaided brand awareness for Neurobion and Evion
Market Cap
₹8,972 Cr
P / E (TTM)
25.1×
EV / EBITDA
17.1×
Div Yield
3.79%
Growth
14.2%▲
Revenue 5y CAGR
PAT +18.0% · EBITDA +17.3%
Quality
76.8%▲
ROCE (FY26)
ROE 62.3% · margin 33.7%
Leverage
0.00·
Debt / Equity · low
Net cash ₹177 Cr
Revenue FY21→FY26
1.9×▲
Margin +3.5 pts
₹723 Cr → ₹1,408 Cr
Moves on a normal day
0.82%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#64/158
P/B#155/163
ROCE#2/183
ROE#3/166
Debt / Equity#1/166
EBITDA margin#14/165
Revenue growth#104/161
Profit growth#67/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 14% a year over 5 years
Profit compounding 18% a year over 5 years
Returns on capital 76.8%
#2 of 183 in Pharmaceuticals on the latest reported figures
No borrowings on the balance sheet
lower than 79% of its 166 Pharmaceuticals peers
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

PGHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from PROCTER & GAMBLE HEALTH L's filed financials and exchange disclosures

What does PROCTER & GAMBLE HEALTH L do?

PROCTER & GAMBLE HEALTH L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol PGHL.

Is PROCTER & GAMBLE HEALTH L profitable?

Yes. Over the trailing twelve months PROCTER & GAMBLE HEALTH L reported a net profit of ₹357 Cr on revenue of ₹1,433 Cr.

Does PROCTER & GAMBLE HEALTH L pay a dividend?

Yes. The dividend yield is 3.79% at the current price. It paid out 104% of its profit as dividend in FY26.

Is PROCTER & GAMBLE HEALTH L debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹177 Cr of cash.

Is PROCTER & GAMBLE HEALTH L expensive compared with its peers?

On trailing P/E, PROCTER & GAMBLE HEALTH L ranks 64 of 158 in Pharmaceuticals — cheaper than 60% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the PROCTER & GAMBLE HEALTH L share price move in a day?

On a typical session PROCTER & GAMBLE HEALTH L moves 0.82% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

When are PROCTER & GAMBLE HEALTH L's next results?

Financial Results on Mon, 2 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track PROCTER & GAMBLE HEALTH L's announcements?

Every NSE and BSE filing by PROCTER & GAMBLE HEALTH L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.